| Ionis Gets $25M From GSK for Experimental Hepatitis B Program | Sarah de Crescenzo | 08/27/19 | San Diego |
| Janssen Reaches $250M Deal for Rights to Arrowhead’s Hep B RNAi Drug | Jeff Buchanan | 10/04/18 | Wisconsin |
| Arrowhead Shares Pop on Early Clinical Data for Hepatitis B Drug | Jeff Buchanan | 09/06/18 | Wisconsin |
| Bio Roundup: Alnylam’s Moment, Read on Rebates, Skinny Plans & More | Alex Lash | 08/03/18 | National |
| Save $100 Today on “What’s Hot in Boston Biotech” on May 16 | Ashley Gentile | 05/02/18 | Boston |
| Agenda Posted for Xconomy’s What’s Hot in Boston Biotech on May 16 | Ashley Gentile | 04/19/18 | Boston |
| Join Feng Zhang, Eric Lander, Craig Mello & More at What’s Hot in Boston Biotech | Ashley Gentile | 03/19/18 | Boston |
| LGC Acquires Lucigen, Marking Latest Exit for CEO Ralph Kauten | Jeff Buchanan | 02/16/18 | Wisconsin |
| Arrowhead Plans Return to Clinic With New Study of Hep B Drug | Jeff Buchanan | 02/16/18 | Wisconsin |
| Arcturus Terminates CEO, Names Mark Herber as Interim President | Bruce V. Bigelow | 02/02/18 | San Diego |
| CRISPR Could Soon Charge into Hearing Loss Drug Race, New Study Suggests | Corie Lok | 12/20/17 | National |
| Promega, Cellectar, Blockchain, & More: This Week’s WI Watchlist | Jeff Buchanan | 12/08/17 | Wisconsin |
| Arrowhead Pharma Reveals Data It Hopes Will Aid New Hepatitis B Drug | Jeff Buchanan | 12/06/17 | Wisconsin |
| Eyeing a Comeback, Arrowhead Bets on New RNAi Delivery Tool | Jeff Buchanan | 09/19/17 | Wisconsin |
| Arrowhead Nets $9.6M Investment From U.K.-Based Silence Therapeutics | Jeff Buchanan | 01/09/17 | Wisconsin |
| 14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) | Alex Lash | 12/22/16 | National |
| Arrowhead Chief Scientific Officer David Lewis Among 34 Laid Off | Jeff Buchanan | 12/01/16 | Wisconsin |
| Arrowhead’s Future Could Now Ride on Progress of Amgen Partnership | Jeff Buchanan | 11/30/16 | Wisconsin |
| Arrowhead Teams Up with Amgen to Develop Cardiovascular Drugs | Jeff Buchanan | 09/29/16 | Wisconsin |
| Redox, Cellectar, Shine, & PeptiMed: This Week’s Wisconsin Watchlist | Jeff Buchanan | 06/27/16 | Wisconsin |
| With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets | Ben Fidler | 04/13/16 | Boston |
| Gene Editing Execs Talk Scientific, Regulatory Hurdles At BIO Panel | Ben Fidler | 02/10/16 | Boston |
| Ahead of Rivals, Arrowhead Unveils Clinical Data for Hepatitis B Drug | Jeff Buchanan | 09/24/15 | Wisconsin |
| East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston |
| Wisconsin Roundup: Exact Sciences, State Budget, Lucigen, & More | Jeff Bauter Engel | 07/08/15 | Wisconsin |
| Wisconsin Roundup: Arrowhead, Cellular Dynamics, Madworks, & More | Jeff Bauter Engel | 04/14/15 | Wisconsin |
| Arrowhead’s Novartis RNAi Deal: Big Boost or ‘Stale Potato Chips’? | Jeff Bauter Engel | 03/09/15 | Wisconsin |
| Wisconsin Roundup: Exact Sciences, Arrowhead, MCW, Marquette, & More | Jeff Bauter Engel | 02/24/15 | Wisconsin |
| Wisconsin Roundup: Okanjo, Arrowhead, Cellular Dynamics, & More | Jeff Bauter Engel | 01/14/15 | Wisconsin |
| Arrowhead, Despite Ailing Stock, Reloads in RNAi Hepatitis B Fight | Jeff Bauter Engel | 12/19/14 | Wisconsin |
